meta-analytic approaches, the validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in colorectal cancer. The first dataset (ACCENT data) contained data for 10,255 patients included in 10 early colon cancer trials. It is a subset of data analysed by Sargent et al. 12 Table 1 presents a short overview of sample sizes and treatments used in each study. The trials accrued patients between 1977 and 1998 (median follow-up 10.4 years). A more detailed description is provided by Sargent et al. 12 The second (MAGIC) dataset included data for 3,089 patients enrolled in 10 advanced colorectal cancer trials. All trials had a 5FU+leucovorin treatment group ( Table 2) . Seven of them compared 5FU + leucovorin with 5FU alone (1744 patients), while the remaining three compared 5FU + leucovorin with raltitrexed (1345 patients). They accrued patients between 1981 and 1990 (median follow-up 30.4 months). A meta-analysis of trials comparing 5FU+leucovorin with 5FU was previously reported. 13 The other three trials were those carried out for the registration of the new drug tomudex (studies 3, 10, and 12 in Cunningham et al). 14 The papers published in this issue of Statistical Methods in Medical Research present details of the analyses and conclusions given during the IBC session. They offer an overview of the meta-analytic approaches currently available for the validation of surrogate endpoints. Also, they allow comparisons of the relative merits of the different approaches. Accompanying papers, written by our colleagues clinicians, offer a complementary view on the validation of surrogate endpoints from a clinical practice perspective.
